Medication info

Amikabon Injection (Ibandronate Sodium Monohydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Huons Co., Ltd.
Appearance
An injection that appears as a colorless, transparent solution in a colorless, transparent glass prefilled syringe with a single-use syringe needle attached.
Packaging
3mL/glass prefilled syringe x 1
Approval status
Active

MFDS item code 201402517 · Notified 2014.06.03 · Insurance code 670606941

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; use of this medicine is therefore not recommended in these patients. Older adults No dose adjustment is required.
Child administration
The efficacy and safety of this medicine in children aged 18 years or younger have not been studied.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women. It helps increase bone density and reduce the risk of fractures. Therefore, it is effective in preventing fractures caused by osteoporosis.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. There is insufficient clinical experience in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min; use of this medicine is therefore not recommended in these patients. Older adults No dose adjustment is required.

Child administration

The efficacy and safety of this medicine in children aged 18 years or younger have not been studied.

Precautions

This medication must be administered through intravenous injection. Care must be taken as administration into the arteries or around the veins may cause damage to the surrounding tissues. Individuals allergic to this medication or its components should not use it. Additionally, patients with untreated hypocalcemia, where blood calcium levels are low, should not take this medication. Using this medication may lead to gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation. Musculoskeletal adverse reactions may include myalgia, arthralgia, and musculoskeletal pain. Some patients may experience influenza-like symptoms, including arthralgia, myalgia, fever, chills, fatigue, nausea, loss of appetite, and bone pain. These symptoms are usually transient and mild, resolving without treatment. Long-term use of this medication may rarely result in osteonecrosis of the jaw or osteonecrosis of the external auditory canal. Patients with cancer or those undergoing chemotherapy, radiation therapy, steroid treatment, or who have poor oral hygiene are at greater risk, thus a dental examination is required prior to administration. During the administration of this medication, it is advisable to avoid excessive dental treatment, and if osteonecrosis is suspected, immediate consultation with medical personnel is necessary. Additionally, this medication may temporarily lower serum calcium levels, so patients with hypocalcemia or bone and mineral metabolism disorders must be treated prior to administration. Sufficient intake of calcium and vitamin D is important, and supplements should be taken if necessary. This medication has been associated with atypical fractures in some patients, such as in the femur and humerus; therefore, if persistent pain in the thigh or groin occurs, assessment should be undertaken. The safety of this medication in pregnant or breastfeeding women has not been established, so it is advisable not to use it. This medication is primarily eliminated through the kidneys and does not undergo metabolism in the liver, so patients with impaired renal function require regular monitoring. In case of overdose, there may be toxicity to the kidneys and liver, necessitating careful monitoring, and appropriate treatment should be provided if electrolyte abnormalities like hypocalcemia occur. This medication has low interaction risks with other medications, but administration should be in accordance with a physician's instructions, and its effects on driving or operating machinery are not known. Finally, this medication should not be mixed with solutions that contain calcium or other drugs, and must be administered only via intravenous injection. After use, the syringe and needle should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, hives, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical femoral fractures, atypical fractures of the iliac bone, dizziness, optic nerve atrophy, lower motor neuron lesions, tremors, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin peeling, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture, and it is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

An injection that appears as a colorless, transparent solution in a colorless, transparent glass prefilled syringe with a single-use syringe needle attached.

Package unit

3mL/glass prefilled syringe x 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.